Cargando…

L/N-Type Calcium Channel Blocker Cilnidipine Added to Renin-Angiotensin Inhibition Improves Ambulatory Blood Pressure Profile and Suppresses Cardiac Hypertrophy in Hypertension with Chronic Kidney Disease

Ambulatory blood pressure (BP) and heart rate (HR) profile are proposed to be related to renal deterioration and cardiovascular complication in hypertension and chronic kidney disease (CKD). In this study, we examined the beneficial effects cilnidipine, a unique L/N-type calcium channel blocker (CCB...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanaoka, Tomohiko, Tamura, Kouichi, Wakui, Hiromichi, Ohsawa, Masato, Azushima, Kengo, Uneda, Kazushi, Kobayashi, Ryu, Fujikawa, Tetsuya, Tsurumi-Ikeya, Yuko, Maeda, Akinobu, Yanagi, Mai, Toya, Yoshiyuki, Umemura, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759940/
https://www.ncbi.nlm.nih.gov/pubmed/23959116
http://dx.doi.org/10.3390/ijms140816866
_version_ 1782282715522924544
author Kanaoka, Tomohiko
Tamura, Kouichi
Wakui, Hiromichi
Ohsawa, Masato
Azushima, Kengo
Uneda, Kazushi
Kobayashi, Ryu
Fujikawa, Tetsuya
Tsurumi-Ikeya, Yuko
Maeda, Akinobu
Yanagi, Mai
Toya, Yoshiyuki
Umemura, Satoshi
author_facet Kanaoka, Tomohiko
Tamura, Kouichi
Wakui, Hiromichi
Ohsawa, Masato
Azushima, Kengo
Uneda, Kazushi
Kobayashi, Ryu
Fujikawa, Tetsuya
Tsurumi-Ikeya, Yuko
Maeda, Akinobu
Yanagi, Mai
Toya, Yoshiyuki
Umemura, Satoshi
author_sort Kanaoka, Tomohiko
collection PubMed
description Ambulatory blood pressure (BP) and heart rate (HR) profile are proposed to be related to renal deterioration and cardiovascular complication in hypertension and chronic kidney disease (CKD). In this study, we examined the beneficial effects cilnidipine, a unique L/N-type calcium channel blocker (CCB), in addition to renin-angiotensin system inhibitors, on ambulatory BP and HR profile, as well as cardiorenal function in hypertensive CKD patients. Forty-five patients were randomly assigned to the cilnidipine replacement group (n = 21) or the control CCBs group (n = 24) during a 24-week active treatment period. Although clinical BP values were similar in the cilnidipine and control CCBs groups after the treatment period, the results of ambulatory BP monitoring showed that the 24-h and daytime systolic BP levels in the cilnidipine group were significantly lower compared with the control group after the study. Furthermore, the left ventricular mass index (LVMI) was significantly decreased in the cilnidipine group compared to the control group after the study (LVMI, 135.3 ± 26.4 versus 181.2 ± 88.4, p = 0.031), with a significant difference in the changes in the LVMI between the cilnidipine and control groups (change in LVMI, −12.4 ± 23.7 versus 26.2 ± 64.4, p = 0.007). These results indicate that cilnidipine is beneficial for the suppression of pathological cardiac remodeling, at least partly, via a superior improving effect on ambulatory BP profile compared with control CCBs in hypertensive CKD patients.
format Online
Article
Text
id pubmed-3759940
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-37599402013-09-03 L/N-Type Calcium Channel Blocker Cilnidipine Added to Renin-Angiotensin Inhibition Improves Ambulatory Blood Pressure Profile and Suppresses Cardiac Hypertrophy in Hypertension with Chronic Kidney Disease Kanaoka, Tomohiko Tamura, Kouichi Wakui, Hiromichi Ohsawa, Masato Azushima, Kengo Uneda, Kazushi Kobayashi, Ryu Fujikawa, Tetsuya Tsurumi-Ikeya, Yuko Maeda, Akinobu Yanagi, Mai Toya, Yoshiyuki Umemura, Satoshi Int J Mol Sci Article Ambulatory blood pressure (BP) and heart rate (HR) profile are proposed to be related to renal deterioration and cardiovascular complication in hypertension and chronic kidney disease (CKD). In this study, we examined the beneficial effects cilnidipine, a unique L/N-type calcium channel blocker (CCB), in addition to renin-angiotensin system inhibitors, on ambulatory BP and HR profile, as well as cardiorenal function in hypertensive CKD patients. Forty-five patients were randomly assigned to the cilnidipine replacement group (n = 21) or the control CCBs group (n = 24) during a 24-week active treatment period. Although clinical BP values were similar in the cilnidipine and control CCBs groups after the treatment period, the results of ambulatory BP monitoring showed that the 24-h and daytime systolic BP levels in the cilnidipine group were significantly lower compared with the control group after the study. Furthermore, the left ventricular mass index (LVMI) was significantly decreased in the cilnidipine group compared to the control group after the study (LVMI, 135.3 ± 26.4 versus 181.2 ± 88.4, p = 0.031), with a significant difference in the changes in the LVMI between the cilnidipine and control groups (change in LVMI, −12.4 ± 23.7 versus 26.2 ± 64.4, p = 0.007). These results indicate that cilnidipine is beneficial for the suppression of pathological cardiac remodeling, at least partly, via a superior improving effect on ambulatory BP profile compared with control CCBs in hypertensive CKD patients. Molecular Diversity Preservation International (MDPI) 2013-08-16 /pmc/articles/PMC3759940/ /pubmed/23959116 http://dx.doi.org/10.3390/ijms140816866 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland http://creativecommons.org/licenses/by/3.0 This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Kanaoka, Tomohiko
Tamura, Kouichi
Wakui, Hiromichi
Ohsawa, Masato
Azushima, Kengo
Uneda, Kazushi
Kobayashi, Ryu
Fujikawa, Tetsuya
Tsurumi-Ikeya, Yuko
Maeda, Akinobu
Yanagi, Mai
Toya, Yoshiyuki
Umemura, Satoshi
L/N-Type Calcium Channel Blocker Cilnidipine Added to Renin-Angiotensin Inhibition Improves Ambulatory Blood Pressure Profile and Suppresses Cardiac Hypertrophy in Hypertension with Chronic Kidney Disease
title L/N-Type Calcium Channel Blocker Cilnidipine Added to Renin-Angiotensin Inhibition Improves Ambulatory Blood Pressure Profile and Suppresses Cardiac Hypertrophy in Hypertension with Chronic Kidney Disease
title_full L/N-Type Calcium Channel Blocker Cilnidipine Added to Renin-Angiotensin Inhibition Improves Ambulatory Blood Pressure Profile and Suppresses Cardiac Hypertrophy in Hypertension with Chronic Kidney Disease
title_fullStr L/N-Type Calcium Channel Blocker Cilnidipine Added to Renin-Angiotensin Inhibition Improves Ambulatory Blood Pressure Profile and Suppresses Cardiac Hypertrophy in Hypertension with Chronic Kidney Disease
title_full_unstemmed L/N-Type Calcium Channel Blocker Cilnidipine Added to Renin-Angiotensin Inhibition Improves Ambulatory Blood Pressure Profile and Suppresses Cardiac Hypertrophy in Hypertension with Chronic Kidney Disease
title_short L/N-Type Calcium Channel Blocker Cilnidipine Added to Renin-Angiotensin Inhibition Improves Ambulatory Blood Pressure Profile and Suppresses Cardiac Hypertrophy in Hypertension with Chronic Kidney Disease
title_sort l/n-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759940/
https://www.ncbi.nlm.nih.gov/pubmed/23959116
http://dx.doi.org/10.3390/ijms140816866
work_keys_str_mv AT kanaokatomohiko lntypecalciumchannelblockercilnidipineaddedtoreninangiotensininhibitionimprovesambulatorybloodpressureprofileandsuppressescardiachypertrophyinhypertensionwithchronickidneydisease
AT tamurakouichi lntypecalciumchannelblockercilnidipineaddedtoreninangiotensininhibitionimprovesambulatorybloodpressureprofileandsuppressescardiachypertrophyinhypertensionwithchronickidneydisease
AT wakuihiromichi lntypecalciumchannelblockercilnidipineaddedtoreninangiotensininhibitionimprovesambulatorybloodpressureprofileandsuppressescardiachypertrophyinhypertensionwithchronickidneydisease
AT ohsawamasato lntypecalciumchannelblockercilnidipineaddedtoreninangiotensininhibitionimprovesambulatorybloodpressureprofileandsuppressescardiachypertrophyinhypertensionwithchronickidneydisease
AT azushimakengo lntypecalciumchannelblockercilnidipineaddedtoreninangiotensininhibitionimprovesambulatorybloodpressureprofileandsuppressescardiachypertrophyinhypertensionwithchronickidneydisease
AT unedakazushi lntypecalciumchannelblockercilnidipineaddedtoreninangiotensininhibitionimprovesambulatorybloodpressureprofileandsuppressescardiachypertrophyinhypertensionwithchronickidneydisease
AT kobayashiryu lntypecalciumchannelblockercilnidipineaddedtoreninangiotensininhibitionimprovesambulatorybloodpressureprofileandsuppressescardiachypertrophyinhypertensionwithchronickidneydisease
AT fujikawatetsuya lntypecalciumchannelblockercilnidipineaddedtoreninangiotensininhibitionimprovesambulatorybloodpressureprofileandsuppressescardiachypertrophyinhypertensionwithchronickidneydisease
AT tsurumiikeyayuko lntypecalciumchannelblockercilnidipineaddedtoreninangiotensininhibitionimprovesambulatorybloodpressureprofileandsuppressescardiachypertrophyinhypertensionwithchronickidneydisease
AT maedaakinobu lntypecalciumchannelblockercilnidipineaddedtoreninangiotensininhibitionimprovesambulatorybloodpressureprofileandsuppressescardiachypertrophyinhypertensionwithchronickidneydisease
AT yanagimai lntypecalciumchannelblockercilnidipineaddedtoreninangiotensininhibitionimprovesambulatorybloodpressureprofileandsuppressescardiachypertrophyinhypertensionwithchronickidneydisease
AT toyayoshiyuki lntypecalciumchannelblockercilnidipineaddedtoreninangiotensininhibitionimprovesambulatorybloodpressureprofileandsuppressescardiachypertrophyinhypertensionwithchronickidneydisease
AT umemurasatoshi lntypecalciumchannelblockercilnidipineaddedtoreninangiotensininhibitionimprovesambulatorybloodpressureprofileandsuppressescardiachypertrophyinhypertensionwithchronickidneydisease